2-fluoro-4-isocyano-1-methylbenzene | 1187843-12-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-fluoro-4-isocyano-1-methylbenzene
• CAS: 1187843-12-4
• 化学式: C₈H₆FN
• mdl: MFCD08059063
• 分子量: 135.141
• InChiKey: AAOCSYVQRDOBTB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  4.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  烟酸 、 2-fluoro-4-isocyano-1-methylbenzene 、 3,4-二氯苯甲醛 在 氨 作用下， 以 2,2,2-三氟乙醇 、 水 为溶剂， 生成 N-(1-(3,4-dichlorophenyl)-2-((3-fluoro-4-methylphenyl)amino)-2-oxoethyl)nicotinamide
  参考文献：
  名称：

  Ugi Reactions with Ammonia Offer Rapid Access to a Wide Range of 5-Aminothiazole and Oxazole Derivatives

  摘要：

  A series of Ugi reactions has been successfully performed using ammonia as the amine component, employing 2,2,2-trifluoroethanol its a non-nucleophilic solvent in order to suppress known side reactions. Utilizing concentrated aqueous ammonia its it convenient Source, this approach offered a simple, one-step assembly of Ugi adducts suitable for elaboration into it variety of 5-aminoazole compounds through postcondensation modifications. Free or N-substituted 5-aminothiazoles and 5-(trifluoroacetamido)oxazoles were all prepared by this improved methodology. The scope of the synthetic route developed and application of the different products are discussed.

  DOI：

  10.1021/jo9014529
• 作为产物：
  描述：

  3-Fluor-4-methyl-formanilid 在 三乙胺 、 三氯氧磷 作用下， 以 二氯甲烷 为溶剂， 反应 0.07h， 以85%的产率得到2-fluoro-4-isocyano-1-methylbenzene
  参考文献：
  名称：

  异氰化物2.0

  摘要：

  异氰酸酯官能团由于其在类胡萝卜素和三键特征之间的二分法而具有亲核和亲电子末端碳，在有机化学中表现出不同寻常的反应性，例如在Ugi反应中。不幸的是，仅按比例使用几种异氰酸酯妨碍了有关该官能团引人入胜的反应性的新发现。具有多个官能团的多种异氰酸酯的合成漫长，效率低下，并使化学家暴露于危险的烟雾中。在这里，我们提出了一种创新的异氰酸酯合成方法，它通过避免在96孔微量滴定板中以0.2 mmol规模在0.5 mol克规模进行平行合成而避免的水后处理，克服了这些问题。我们方法的优势包括提高合成速度，在非常温和的条件下可以使用迄今为止从未有过的未知或高度反应性的异氰酸酯类，可以快速使用大量官能化的异氰酸酯，具有较高的收率，高纯度，经过验证的5个数量级以上的可扩展性，增加的安全性和较少的反应浪费，从而大大减少了环境脚印。例如，迄今为止认为是不稳定的2-异氰基嘧啶，2-酰基苯基异氰酸酯，甚至邻-异氰基苯甲醛

  DOI：

  10.1039/d0gc02722g

文献信息

• 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
  申请人：Schering Corporation

  公开号：US20040220194A1

  公开（公告）日：2004-11-04

  Compounds having the structural formula I 1 or a pharmaceutically acceptable salt thereof, wherein R is 2 R 1 , R 2 , R 3 , R 4 and R 5 are H, alkyl or alkoxyalkyl; R 6 is H, alkyl, hydroxyalkyl or —CH 2 F; R 7 , R 8 and R 9 are H, alkyl, alkoxy, alkylthio, alkoxyalkyl, halo or —CF 3 ; and Z is optionally substituted aryl, heteroaryl or heteroaryl-alkyl are disclosed. Also disclosed is the use of compounds of formula I in the treatment of central nervous system diseases, in particular Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, and pharmaceutical compositions comprising them.

  具有结构式I或其药用可接受盐的化合物，其中R是R1，R2，R3，R4和R5为H，烷基或烷氧基烷基；R6为H，烷基，羟基烷基或—CH2F；R7，R8和R9为H，烷基，烷氧基，烷硫基，烷氧基烷基，卤素或—CF3；以及Z是可选择地取代的芳基，杂环芳基或杂环芳基烷基。还公开了化合物I的应用于治疗中枢神经系统疾病，特别是帕金森病，单独或与其他治疗帕金森病的药剂联合使用，以及包含它们的药物组合物。
• ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
  申请人：Abouabdellah Ahmed

  公开号：US20120295909A1

  公开（公告）日：2012-11-22

  The invention relates to compounds corresponding to the general formula (I): in which R 2 represents a hydrogen, fluorine, hydroxyl, cyano, trifluoromethyl, C 1-6 -alkyl, C 1-6 -alkoxy or —NR 8 R 9 ; n and m represent, independently of one another, an integer equal to 1, 2 or 3, it being understood that the sum m+n is at most equal to 5; A represents a covalent bond, an oxygen, a C 1-6 -alkylene or —O—C 1-6 -alkylene; R 1 represents a phenyl or a heterocycle which is optionally substituted; R 3 represents a hydrogen, fluorine, C 1-6 -alkyl or trifluoromethyl; R 4 represents an optionally substituted 5-membered heterocycle; in the form of the base or of an addition salt with an acid; with the exclusion of 5-methylisoxazol-3-ylmethyl 4-hydroxy-4-(4-chlorophenyl)piperidine-1-carboxylate. The invention also relates to a process for the preparation of the compounds of formula (I), to compositions comprising them and to their therapeutic application.

  本发明涉及与通式（I）相对应的化合物： 其中R2代表氢、氟、羟基、氰基、三氟甲基、C1-6烷基、C1-6烷氧基或—NR8R9；n和m独立地表示为1、2或3的整数，其中m+n的总和最大为5；A代表共价键、氧、C1-6烷基亚基或—O—C1-6烷基亚基；R1代表苯基或可选取代的杂环；R3代表氢、氟、C1-6烷基或三氟甲基；R4代表可选取代的5元杂环；以其碱式或酸盐形式存在；但排除5-甲基异噁唑-3-基甲基4-羟基-4-(4-氯苯基)哌啶-1-羧酸酯。 本发明还涉及制备通式（I）化合物的方法，包括它们的组合物和它们的治疗应用。
• Substituted Pyrrole Derivative
  申请人：Matsunaga Nobuyuki

  公开号：US20080176906A1

  公开（公告）日：2008-07-24

  The present invention provides a novel pyrrole derivative having excellent androgen receptor antagonism, which is represented by the formula: wherein R 1 represents a hydrogen atom, a cyano group or a group represented by the formula COOR A (wherein R A represents an optional substituted C 1-6 alkyl group), R 2 and R 4 are the same or different, and each represents a hydrogen atom, a C 1-6 alkyl group, a C 3-6 cycloalkyl group, a trifluoromethyl group, an amino-C 1-6 alkyl group, a mono- or di-substituted amino-C 1-6 alkyl group, an optionally halogenated C 1-6 alkyl group substituted with an optionally substituted hydroxyl group, a C 2-6 alkenyl group substituted with an optionally substituted hydroxyl group, a C 1-6 alkyl group substituted with an optionally substituted and optionally oxidized thiol group, an optionally substituted with and optionally oxidized thiol group, a cyano group, an acyl group, an optionally substituted oxazolyl group or a 1,3-dioxolan-2-yl group, R 3 represents a group represented by the formula: (wherein X represents a halogen atom, Y represents a carbon atom or a nitrogen atom, Alk represents an optionally substituted C 1-4 alkylene group, and R B represents a hydrogen atom or an acyl group), and R 5 represents a phenyl group which has a cyano group at a 4 -position or a 3 -position thereof, and may be further substituted, or a salt thereof. The present invention also provides an androgen receptor antagonist containing the pyrrole derivative, or a salt thereof.

  本发明提供了一种新型吡咯衍生物，具有优异的雄激素受体拮抗作用，其化学式表示为：其中，R1表示氢原子、氰基或由COORA（其中RA表示可选的取代C1-6烷基基团）表示的基团，R2和R4相同或不同，每个表示氢原子、C1-6烷基基团、C3-6环烷基基团、三氟甲基基团、氨基-C1-6烷基基团、单取代或双取代氨基-C1-6烷基基团、可选卤代的C1-6烷基基团，其被取代的羟基基团也是可选的、可选取代的C2-6烯基基团、被可选取代的硫醇基团取代的C1-6烷基基团、被可选取代的、可选氧化的硫醇基团取代的C1-6烷基基团、氰基、酰基、可选取代的噁唑基团或1,3-二氧杂环戊烷-2-基基团，R3表示由以下公式表示的基团：（其中，X表示卤素原子，Y表示碳原子或氮原子，Alk表示可选取代的C1-4烷基基团，RB表示氢原子或酰基），R5表示在其4-位或3-位具有氰基基团的苯基基团，可以进一步取代，或其盐。本发明还提供了一种含有该吡咯衍生物或其盐的雄激素受体拮抗剂。
• Piperazine derivates and their use for the treatment of neurological and psychiatric diseases
  申请人：Bruton Gordon

  公开号：US20070054917A1

  公开（公告）日：2007-03-08

  The present invention relates to novel piperidine carbonyl piperazine derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.

  本发明涉及具有药理活性的新型哌啶羰基哌嗪衍生物，其制备方法，包含它们的组合物以及它们在神经系统和精神疾病治疗中的应用。
• NOVEL COMPOUNDS AS MODULATORS OF GPR-119
  申请人：NAGARATHNAM Dhanapalan

  公开号：US20130045986A1

  公开（公告）日：2013-02-21

  The present invention relates to novel compounds of formula (A) and (B) as modulators of GPR-119, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of GPR-119 mediated diseases or disorders with them.

  本发明涉及一种公式（A）和（B）的新化合物，作为GPR-119的调节剂，其制备方法，包含它们的制药组合物以及使用它们治疗、预防和/或改善GPR-119介导的疾病或障碍的方法。